Who are CT-P13 SC Auto-injector's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abrilada, Humira, Etanercept (ETN), Infliximab [infliximab biosimilar 3], Etanercept + Methotrexate, Tapered doses of TNFi.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ct-p13-sc-auto-injector.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CT-P13 SC Auto-injector — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CT-P13 SC Auto-injector (CT-P13 SC Auto-injector) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor (monoclonal antibody biosimilar). Area: Immunology.

phase 3 TNF-alpha inhibitor (monoclonal antibody biosimilar) TNF-alpha Immunology Biologic Live · refreshed every 30 min

Target snapshot

CT-P13 SC Auto-injector (CT-P13 SC Auto-injector) — Celltrion. CT-P13 SC is a subcutaneous auto-injector formulation of infliximab, a TNF-alpha inhibitor that blocks tumor necrosis factor signaling to reduce inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CT-P13 SC Auto-injector TARGET	CT-P13 SC Auto-injector	Celltrion	phase 3	TNF-alpha inhibitor (monoclonal antibody biosimilar)	TNF-alpha
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Etanercept (ETN)	Etanercept (ETN)	University of Leeds	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)
Infliximab [infliximab biosimilar 3]	infliximab-infliximab-biosimilar-3	Pfizer	marketed	monoclonal antibody	tumor necrosis factor-alpha (TNF-alpha)
Etanercept + Methotrexate	Etanercept + Methotrexate	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	TNF inhibitor + DMARD combination	TNF-alpha receptor (etanercept); dihydrofolate reductase (methotrexate)
Tapered doses of TNFi	Tapered doses of TNFi	University Health Network, Toronto	marketed	TNF inhibitor (tapered dosing strategy)	TNF-alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor (monoclonal antibody biosimilar) class)

Celltrion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CT-P13 SC Auto-injector — Competitive Intelligence Brief. https://druglandscape.com/ci/ct-p13-sc-auto-injector. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab